- September 14, 2021
Postdoctoral Position Available in Braddock Lab
- May 21, 2021
Faculty Entrepreneurs Receive Research Support from Blavatnik Fund for Innovation at Yale
- May 09, 2019Source: Patch
Eight Finalists Awarded At 2019 Yale Innovation Summit
- April 10, 2019Source: Business Wire
Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders
- October 27, 2016Source: United Press International
Gene-editing technology may help cure blood disorders
Welcome to the Braddock Lab
We study the pathophysiology of benign and malignant hematologic disorders using biochemical and biophysical methods. Recently, we uncovered two endothelial bound enzymes on the cerebral vasculature that induce platelet aggregation via the hydrolysis of a small molecule released by platelets upon degranulation. We have proposed that these enzymes are unrecognized factors capable of inducing central hemostasis/stroke, a hypothesis supported by recent genomic studies revealing genes conferring stroke protection to patients at risk for thrombotic stroke (see press release).
Inozyme Pharmaceuticals aims to develop a therapy for an ultra-rare infant disorder—this is based on the work of Yale University pathologist Demetrios Braddock.
Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease